HIGHLIGHTS
- who: Carolina Velazquez et al. from the Tongji University, China have published the article: BRCA1-methylated triple negative breast cancers previously exposed to neoadjuvant chemotherapy form RAD51 foci and respond poorly to olaparib, in the Journal: (JOURNAL)
- how: (D) tumor volume change under olaparib treatment stratified according the RAD51 foci status. * ***** on top of the graph indicate the level of significance of the t-test. prior NACT the authors cannot conclude on HR restoration due to treatment exposure but the data are in line with previous reports . The data are in perfect concordance with these . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.